Develco Pharma Schweiz
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hauptstrasse 67, Binningen, Basel-Landsc...Phone Number
+41 614255020Website
www.develco.chRevenue
$19.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Develco Pharma Schweiz
Develco Pharma is a private company that develops and produces innovative formulations for pharmaceuticals with known active ingredients. The company is responsible for the entire value chain from development to approval, manufacturing, and delivery, focusing on extended or modified release formulations. It has gained international recognition for its expertise, particularly in treating severe pain and ADHD. Develco Pharma aims to enhance quality of life and ensure sustainable business success through flexible and innovative strategies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Develco Pharma Schweiz your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Develco Pharma Schweiz launches new products
Congratulate Masked Content for being promoted to Masked Content at Develco Pharma Schweiz
Earning: See what the market has to say on Develco Pharma Schweiz recently announced quarterly report
Funding: Get notified immidiatlly once Develco Pharma Schweiz has new funding data
Check out if Develco Pharma Schweiz is spiking on competitors!
Develco Pharma Schweiz, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Develco Pharma Schweiz has recently received funding, and reach out quickly before it becomes old news!
Click to see if Develco Pharma Schweiz had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Develco Pharma Schweiz
Find 2 more new buyers
Company Profile Activity
Activity Insights
Develco Pharma Schweiz is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Develco Pharma Schweiz is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Develco Pharma Schweiz.
Develco Pharma Schweiz Tech Stack
A closer look at the technologies used by Develco Pharma Schweiz
See more technologies
Develco Pharma Schweiz News & Media
Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024
Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in Patients Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in PatientsKetabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO®First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy, safety, and tolerability of add-on treatment with KET01 in 117 patients suffering from Treatment-Resistant Depression (TRD) MUNICH, Germany, June 08, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), together with Develco pharma, today announced the dosing of the first patient in their second Phase 2 trial with oral prolongedHMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study
MUNICH, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, together with Develco Pharma, a company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs, today announced promising top-line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-r
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Develco Pharma Schweiz
Sign Up For FreeTo access detailed company insights
Develco Pharma is a private company that develops and produces innovative formulations for pharmaceuticals with known active ingredients. The company is responsible for the entire value chain from development to approval, manufacturing, and delivery, focusing on extended or modified release formulations. It has gained international recognition for... Read More
